New Fully Automated Preparation of High Apparent Molar Activity 68 Ga-FAPI-46 on a Trasis AiO Platform

Chiara Da Pieve, Marta Costa Braga, David R Turton, Frank A Valla, Pinar Cakmak, Karl-Heinz Plate, Gabriela Kramer-Marek Abstract:A large number of applications for fibroblast activation protein inhibitors (FAPI)-based PET agents have been evaluated in conditions ranging from cancer to non-malignant diseases such as [...]

January 20th, 2022|Publications|

Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review

Liang Zhao, Jianhao Chen, Yizhen Pang, Kaili Fu, Qihang Shang, Hua Wu, Long Sun, Qin Lin, Haojun Chen Abstract: In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have shown promising results in the diagnosis of cancer and several other diseases, making them [...]

January 9th, 2022|Publications|

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?

Katharina Dendl 1,2 Stefan A. Koerber 3,4,5 Clemens Kratochwil 1 Jens Cardinale 1,2 Rebecca Finck 1 Mardjan Dabir 2 Emil Novruzov 2Tadashi Watabe 6 Vasko Kramer 7,8 Peter L. Choyke 9 Uwe Haberkorn 1,10,11 and Frederik L. Giesel 1,2 Abstract:A fibroblast activation protein (FAP) [...]

November 2nd, 2021|Publications|

New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress

Surachet Imlimthan, Euy Sung Moon, Hendrik Rathke, Ali Afshar-Oromieh, Frank Rösch, Axel Rominger, Eleni Gourni Abstract: Over the past decade, the tumor microenvironment (TME) has become a new paradigm of cancer diagnosis and therapy due to its unique biological features, mainly the interconnection between [...]

October 5th, 2021|Publications|

FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

Frederik L Giesel 1, Sebastian Adeberg 2 3 4 5, Mustafa Syed 2 4, Thomas Lindner 1, Luis David Jiménez-Franco 6, Eleni Mavriopoulou 1, Fabian Staudinger 1, Eric Tonndorf-Martini 2 4, Sebastian Regnery 2 4, Stefan Rieken 2 5 7, Rami El Shafie 2 5, Manuel Röhrich 1, Paul Flechsig 1, Andreas Kluge 6, Annette Altmann 1, Jürgen Debus 2 3 4 5, Uwe Haberkorn 8 9, Clemens Kratochwil 1 Abstract: 68Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life [...]

February 24th, 2021|Publications|

68 Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [ 18 F] FDG PET/CT

Guochang Wang # 1, Xiao Jin # 1, Hua Zhu 1, Shuailiang Wang 1, Jin Ding 1, Yan Zhang 1, Zhi Yang 2, Xuejuan Wang 3 Article available for purchase or with subscription. Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian, Beijing, 100142, China. [...]

February 24th, 2021|Publications|

Fibroblast Activation Protein-Targeted PET/CT with 68 Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18 F-FDG PET/CT

Yaping Luo 1 2, Qingqing Pan 1 2, Huaxia Yang 3, Linyi Peng 3, Wen Zhang 3, Fang Li 4 2 Abstract: IgG4-related disease (RD) is characterized by lymphoplasmacytic infiltration enriched in IgG4-positive plasma cells and variable degrees of fibrosis with a characteristic storiform pattern. Since fibrosis is an important feature of IgG4-RD, we performed a prospective cohort [...]

February 6th, 2021|Publications|

[ 18 F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions

Bing Hao 1, Xiurong Wu 2, Yizhen Pang 1, Long Sun 1, Hua Wu 1, Weipeng Huang # 3, Haojun Chen # 4 Article available for purchase or with subscription. Affiliations: Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China. Department of [...]

February 2nd, 2021|Publications|

Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer

Artineh Hayrapetian 1, Mark D Girgis, Jane Yanagawa, Samuel W French, Heinrich R Schelbert 1, Martin S Auerbach 1, Johannes Czernin, Jeremie Calais Abstract: A 71-year-old man underwent 18F-FDG and 68Ga-FAPI-46 PET/CT for initial staging prior to surgery of a squamous cell carcinoma of the lower esophagus under the prospective study NCT04147494. Both scans showed [...]

February 1st, 2021|Publications|

Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18 F-Labeled FAP Inhibitor

Johannes Toms 1, Jürgen Kogler 1, Simone Maschauer 1, Christoph Daniel 2, Christian Schmidkonz 3, Torsten Kuwert 3, Olaf Prante 4 3 Fibroblast activation protein (FAP) has emerged as an interesting molecular target used in the imaging and therapy of various types of cancers. 68Ga-labeled chelator-linked FAP inhibitors (FAPIs) have been successfully applied to PET imaging of various tumor [...]

December 6th, 2020|Publications|


Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs.

Go to Top